3SOF

updated chart look...

A 'Pandemic' Now Declared, Focus Back on Swine Flu Stocks
On Friday June 12, 2009, 12:00 pm EDT

The H1N1 virus is officially a pandemic, and vaccine stocks are responding.

Swine flu stocks are up again today, with some extending weekly gains to more than 20%. A number of companies released good news to end the week. From small-cap players to multi-billion dollar giants, shares are up big on high volume. Novartis (NYSE: NVS) announced today that it will have a swine flu vaccine ready by this fall. Shares are up by 4% on the news.

On Thursday, the World Health Organization raised its alert level on the virus to "Phase 6," indicating that it has officially become a pandemic.

As a whole the Swine Flu and Bird Flu Stocks Index is up by 2.5%. It is now beating the S&P 500 by 35.5% over the last month.

Generex Biotechnology (NASDAQ: GNBT) is leading the Index today with 10% gains. The company was granted five new patents for its drug delivery systems. The patents were awarded in Canada, Australia, New Zealand, Brazil, and Lebanon. The stock is still in negative territory this week by -3%.

Sinovac Biotech (AMEX: SVA) is adding another 3% to its industry-leading 30% weekly rally. On Monday the company announced that it had begun production of a swine flu vaccine, and noted that it could produce up to 30 million doses per year.

Vical (NASDAQ: VICL) has fallen from earlier highs, and is now trading up fractionally. Thomas Weisel initiated coverage of the company today with an Overweight rating and a $5 price target. The analyst cited Vical's proprietary technology, strategic partnerships, and licensing agreements.

GlaxoSmithKline (NYSE: GSK) and Hemispherx Biopharma (AMEX: HEB) are both ahead by more than 4% today.

Pure Bioscience (NASDAQ: PURE) and AVI Biopharma (NASDAQ: AVII) are industry laggards today, falling by -3% and -6% respectively.

As of this writing the Swine Flu and Bird Flu Stocks Index is a top-three performing tickerspy Index over the last month, gaining 39.5%.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.
http://www.tickerspy.com/index/Swine-Flu-and-Bird-Flu-Stocks?refer=2028Y3

A 'Pandemic' Now Declared, Focus Back on Swine Flu Stocks
On Friday June 12, 2009, 12:00 pm EDT

The H1N1 virus is officially a pandemic, and vaccine stocks are responding.

Swine flu stocks are up again today, with some extending weekly gains to more than 20%. A number of companies released good news to end the week. From small-cap players to multi-billion dollar giants, shares are up big on high volume. Novartis (NYSE: NVS) announced today that it will have a swine flu vaccine ready by this fall. Shares are up by 4% on the news.

On Thursday, the World Health Organization raised its alert level on the virus to "Phase 6," indicating that it has officially become a pandemic.

As a whole the Swine Flu and Bird Flu Stocks Index is up by 2.5%. It is now beating the S&P 500 by 35.5% over the last month.

Generex Biotechnology (NASDAQ: GNBT) is leading the Index today with 10% gains. The company was granted five new patents for its drug delivery systems. The patents were awarded in Canada, Australia, New Zealand, Brazil, and Lebanon. The stock is still in negative territory this week by -3%.

Sinovac Biotech (AMEX: SVA) is adding another 3% to its industry-leading 30% weekly rally. On Monday the company announced that it had begun production of a swine flu vaccine, and noted that it could produce up to 30 million doses per year.

Vical (NASDAQ: VICL) has fallen from earlier highs, and is now trading up fractionally. Thomas Weisel initiated coverage of the company today with an Overweight rating and a $5 price target. The analyst cited Vical's proprietary technology, strategic partnerships, and licensing agreements.

GlaxoSmithKline (NYSE: GSK) and Hemispherx Biopharma (AMEX: HEB) are both ahead by more than 4% today.

Pure Bioscience (NASDAQ: PURE) and AVI Biopharma (NASDAQ: AVII) are industry laggards today, falling by -3% and -6% respectively.

As of this writing the Swine Flu and Bird Flu Stocks Index is a top-three performing tickerspy Index over the last month, gaining 39.5%.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.
http://www.tickerspy.com/index/Swine-Flu-and-Bird-Flu-Stocks?refer=2028Y3
   

updated chart look...

updated chart look...

updated chart...

ouch! 

very nice.. congrats



Sinovac wins Chinese supply contract for seasonal flu vaccine
Monday , August 31, 2009 13:07ET

Aug 31, 2009 (Datamonitor via COMTEX) -- Chinese biopharmaceutical company Sinovac Biotech has reported that the Beijing Public Health Bureau has selected Sinovac as one of the four manufacturers to supply Anflu, the company's seasonal influenza vaccine, for the benefit of the citizens of Beijing.

The Beijing Public Health Bureau has completed the bidding process for the purchase of flu vaccines and corresponding services for 2009 on August 26, 2009. The agreement will be executed after the public notice period.

Under the bureau's plan, people over the age of 60, as well as elementary and secondary school students, will be inoculated with the influenza vaccine at no charge. Previously, school students were inoculated with the influenza vaccine at a charge of RMB20 per person with allowances from the bureau.

Weidong Yin, president and CEO of Sinovac, said: "As part of our mission to develop vaccines to combat the spread of disease in China and around the world, we are pleased to again be among the seasonal flu suppliers to the Beijing government.

"We are confident of our flexibility to be able to fill large seasonal flu vaccine orders while also executing the R&D and large-scale production of our H1N1 vaccine. Our ability to produce multiple sophisticated and high-quality vaccines simultaneously is further proof that Sinovac is a leading vaccine provider."

Nice indeed...
Watch for the dip...pullback...Maybe worth a buy.

Outlook for Sinovac Biotech Ltd. (SVA)

is an emerging China-based biotechnology company focused on the development, manufacturing and commercialization of human vaccines against infectious diseases. The Company's portfolio of products consists of vaccines against the hepatitis A, hepatitis B and influenza viruses. Its PanfluTM vaccine, which protects against the H5N1 influenza virus, has already been approved for government stockpiling.

The Company is also developing human vaccines for Enterovirus 71 (EV71), Japanese encephalitis and rabies. SVA is the first company in the world to have been granted permission to begin clinical trials for a vaccine to prevent Severe Acute Respiratory Syndrome (SARS), and the only company in China to develop a human use avian flu vaccine and successfully obtain the production approval from Chinese government.

Incorporated in 1999, the Company is headquartered in Beijing, the People's Republic of China.


Financial Summary:
In an unaudited second quarter 2009 financial report, SVA reported that its sales for the quarter increased 21% to $20 million, while sales for the six-month period increased 5% to $26.6 million. Meanwhile, net income attributable to the shareholders increased 74% to $5.8 million in the second quarter, with diluted EPS of $0.14. SVA chairman and CEO Weidong Yin partly attributed the revenue growth to increased sales of the Company's inactivated hepatitis A vaccine to the public market. As of June 30, 2009, the Company had cash and cash equivalents of $46.7 million.

Year on year, the Company's revenue grew 38.63% from $33.54 million to $46.50 million, while net income improved 4.71% from $7.65 million to $8.01 million. Last year, the Company increased its cash reserves by 92.69%, or $15.82 million.

The Company has a Debt to Total Capital ratio of 0.29%, a higher figure than the previous year's 0.03%.


Investment Highlights:
Overview

China-based SVA focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. The Company's portfolio of products consists of vaccines against the hepatitis A, hepatitis B and influenza viruses.

The Company aims to be a leader in the supply of safe and effective vaccines that protect against human diseases. It boasts of vaccines developed with its own intellectual property rights. The Company markets and sells its vaccine products primarily through various provincial and municipal centers in China, and is currently on the process of developing international market to deliver its cost-efficient and high-quality products to other countries.



Chinese Vaccine Industry:

The Chinese vaccine industries have seen higher profit margins, market expansion, and product line extensions during the past 20 years, according to a report by Dr. Liu Jianyuan, a researcher at the National Vaccine & Serum Institute. The report noted that the total vaccine markets have reached 3 billion RMB ($375 million), and the annual market demand for vaccines in China appears to be continuing its 15% annual increase. Separate reports link the boost in the vaccine industry with the emergence of SARS, avian flu, as well as the spread of hepatitis B across China. It was boosted anew with steady spread of the H1N1 virus through the country.


Addressing the Need for Protection against Infectious Diseases

Hepatitis B, a disease caused by HBV hepatitis B virus, is recognized as endemic in China, according to the World Health Organization (WHO). Globally, there are about 350 million chronic carriers of the hepatitis B virus, according to a report by Elsevier Science Ltd. Infection is acquired through exposure to infectious blood or body fluids containing blood. Medical literatures indicate that possible forms of transmission include, but are not limited to, unprotected sexual contact, blood transfusions, re-use of contaminated needles and syringes, and vertical transmission from mother to child during childbirth. Hepatitis B is 100 times more infectious than the AIDS virus, yet it can be prevented by vaccination.

Hepatitis A is an acute infectious disease of the liver caused by the hepatitis A virus (HAV). Although hepatitis A does not have a chronic stage, is not progressive, and does not cause permanent liver damage, the disease still causes considerable morbidity and mortality. Like hepatitis B, infection can be prevented by vaccination.

Influenza: SVA's Anflu(TM) vaccine was developed in response to the fast growing influenza vaccine market in China. On July 22, the Company reported that it initiated dosing in its clinical trial of various Panflu vaccine candidates for pandemic influenza A (H1N1), with results to be reported in September 2009.



Products:

BiliveTM

Bilive is a combined inactivated hepatitis A and B vaccine. It is available in different doses for use in both adults and children. BiliveTM junior is suitable for use in non-immune infants, children and adolescents from one year up to and including 15 years, who are at risk of Hepatitis A and Hepatitis B infection. BiliveTM adult is suitable for use in non-immune adults and adolescents 16 years of age and older, who are at risk of Hepatitis A and Hepatitis B infection. The vaccine can be recommended for persons who remain in the vicinity of HAV and/or HBV, users of illicit intravenous drugs, homosexuals and bisexuals, hemophiliacs who receive therapeutic blood products, persons with nephropathy who receive dialysis treatment, and those persons who receive long-term blood dialysis.


Healive®

Healive® is an inactivated hepatitis A vaccine developed without any preservative. It gained the state certificate as a new drug in 1999 and was launched in 2002. The vaccine provides the same efficiency and long-lasting immune effectiveness as Havrix, with more than 20 years of protection, if calculated according to the international Van Damme formula.


Anflu®

Anflu vaccine is an inactivated split influenza vaccine formulated from three split inactivated virus solutions, developed without preservatives. Over the past two years, the Company has expanded its manufacturing capacity for seasonal influenza vaccine to 5 million doses per year, and the same production line can produce 20 million doses of pandemic influenza vaccine, using a grant from China's National Development and Reform Commission. The Company sold approximately 1.46 million doses of Anflu last year.

Aside from endemic and pandemic viruses of hepatitis and influenza, the Company is also developing human vaccines for Enterovirus 71 (EV71), Japanese encephalitis and rabies, as well as emerging viruses such as SARS and Avian Flu Influenza (bird flu). SVA is the first company in the world to have been granted permission to begin clinical trials for a vaccine to prevent Severe Acute Respiratory Syndrome (SARS), and the only company in China to develop a human use avian flu vaccine and successfully obtain the production approval from Chinese government.



Company Highlight and Recent News:

On August 31, SVA announced its H1N1 vaccine has passed experts evaluation organized by SFDA, China's competent authority of drug regulation, pushing the Company's shares to hit a record high. According to the Company's press release, the H1N1 vaccine's results demonstrated to have a good safety profile and immunogenicity factors that reach the EU criterion after a single shot, with experts unanimously agreeing that the Company's H1N1 vaccine is applicable to all people from three to 60 years of age; the vaccination schedule is a single shot. The Company looks forward to obtaining the production license within one week.

SVA shares were boosted last week, also helping the Swine and Bird Flu Stocks Index to increase 4.5% on news that the Company was chosen as one of the four manufacturers to supply Beijing with seasonal flu vaccine for 2009. According to the report, the Company will provide the city with its split viron vaccine, Anflu®, which is also hoped to provide H1N1 swine flu protection.


Technical Analysis:

SVA has traded between $0.75 and $9.95 over the last 52 weeks. On August 31, SVA set a new 52-week high during trading session when it reached $9.95. Over this period, the share price is up 198.77%.

Currently, the MACD for SVA currently indicates a strong bullish signal for two reasons. First, the MACD is above the signal line, a 9-day moving average. Second, the MACD is above 0, which implies that the underlying moving averages are trending higher.

The stock's Bollinger Bands indicate greater than normal volatility as reflected by an increase in distance between the upper and lower bands. Trading at its upper Bollinger Band, the stock reflects high price relative to its recent price action.

With share prices currently above the stock's 13-day moving average, a bullish trend is indicated. Also, a rising moving average signals that there has been buying interest in this stock.


Comparative Analysis:
SVA has a positive Return on Assets of 13.84%, compared with an industry average of 2.03%; Return on Investment of 22.34%, compared with an industry average of 2.53%; and a Return on Equity of 17.47%, compared with an industry average of 4.36%.

"SVA" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.         
All history on a stock pick in 1 thread is awesome.       

Thank You....and good luck with all your trades....make some $$$ 


I will leave you the chart while I am in this thread.....
Below is the 1 year chart...